FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585046292> ?p ?o ?g. }

• W2585046292 endingPage "1046" @default.
• W2585046292 startingPage "1037" @default.
• W2585046292 abstract "Background & Aims NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. Methods We fed foz/foz and wild-type mice an atherogenic diet for 16 weeks, gavaged MCC950 or vehicle until 24 weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6 weeks and determined the effects on liver fibrosis. Results In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24 weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis. Conclusion MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH. Lay summary Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed non-alcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis. NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. We fed foz/foz and wild-type mice an atherogenic diet for 16 weeks, gavaged MCC950 or vehicle until 24 weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6 weeks and determined the effects on liver fibrosis. In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1β, active caspase-1 and IL-1β increased at 24 weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1β, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1β expression, plasma IL-1β, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1β; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1β, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis. MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH." @default.
• W2585046292 created "2017-02-10" @default.
• W2585046292 creator A5004778423 @default.
• W2585046292 creator A5020671752 @default.
• W2585046292 creator A5029662334 @default.
• W2585046292 creator A5030372642 @default.
• W2585046292 creator A5043687512 @default.
• W2585046292 creator A5053295611 @default.
• W2585046292 creator A5058034348 @default.
• W2585046292 creator A5059298893 @default.
• W2585046292 creator A5072344236 @default.
• W2585046292 creator A5074255400 @default.
• W2585046292 creator A5075412057 @default.
• W2585046292 creator A5077160470 @default.
• W2585046292 creator A5078176598 @default.
• W2585046292 creator A5080269600 @default.
• W2585046292 creator A5090230661 @default.
• W2585046292 date "2017-05-01" @default.
• W2585046292 modified "2023-10-18" @default.
• W2585046292 title "NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice" @default.
• W2585046292 cites W1593760300 @default.
• W2585046292 cites W1908780918 @default.
• W2585046292 cites W1964572117 @default.
• W2585046292 cites W1964710704 @default.
• W2585046292 cites W1968393209 @default.
• W2585046292 cites W1969981758 @default.
• W2585046292 cites W1970253621 @default.
• W2585046292 cites W1972483153 @default.
• W2585046292 cites W1974412717 @default.
• W2585046292 cites W1974826451 @default.
• W2585046292 cites W1975024542 @default.
• W2585046292 cites W1975752601 @default.
• W2585046292 cites W1977508200 @default.
• W2585046292 cites W1984371486 @default.
• W2585046292 cites W1995164074 @default.
• W2585046292 cites W2008580473 @default.
• W2585046292 cites W2010101404 @default.
• W2585046292 cites W2012860738 @default.
• W2585046292 cites W2013907285 @default.
• W2585046292 cites W2024639496 @default.
• W2585046292 cites W2028545985 @default.
• W2585046292 cites W2035030361 @default.
• W2585046292 cites W2042981158 @default.
• W2585046292 cites W2045531934 @default.
• W2585046292 cites W2048104183 @default.
• W2585046292 cites W2056808548 @default.
• W2585046292 cites W2072751867 @default.
• W2585046292 cites W2074203821 @default.
• W2585046292 cites W2093025818 @default.
• W2585046292 cites W2093824918 @default.
• W2585046292 cites W2101341463 @default.
• W2585046292 cites W2106549878 @default.
• W2585046292 cites W2107943478 @default.
• W2585046292 cites W2119370038 @default.
• W2585046292 cites W2119696490 @default.
• W2585046292 cites W2125720510 @default.
• W2585046292 cites W2131372305 @default.
• W2585046292 cites W2133353550 @default.
• W2585046292 cites W2135450217 @default.
• W2585046292 cites W2136354950 @default.
• W2585046292 cites W2137623379 @default.
• W2585046292 cites W2138365442 @default.
• W2585046292 cites W2140637559 @default.
• W2585046292 cites W2144275312 @default.
• W2585046292 cites W2167743390 @default.
• W2585046292 cites W2169624083 @default.
• W2585046292 cites W2205982384 @default.
• W2585046292 cites W4211217520 @default.
• W2585046292 doi "https://doi.org/10.1016/j.jhep.2017.01.022" @default.
• W2585046292 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6536116" @default.
• W2585046292 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28167322" @default.
• W2585046292 hasPublicationYear "2017" @default.
• W2585046292 type Work @default.
• W2585046292 sameAs 2585046292 @default.
• W2585046292 citedByCount "666" @default.
• W2585046292 countsByYear W25850462922017 @default.
• W2585046292 countsByYear W25850462922018 @default.
• W2585046292 countsByYear W25850462922019 @default.
• W2585046292 countsByYear W25850462922020 @default.
• W2585046292 countsByYear W25850462922021 @default.
• W2585046292 countsByYear W25850462922022 @default.
• W2585046292 countsByYear W25850462922023 @default.
• W2585046292 crossrefType "journal-article" @default.
• W2585046292 hasAuthorship W2585046292A5004778423 @default.
• W2585046292 hasAuthorship W2585046292A5020671752 @default.
• W2585046292 hasAuthorship W2585046292A5029662334 @default.
• W2585046292 hasAuthorship W2585046292A5030372642 @default.
• W2585046292 hasAuthorship W2585046292A5043687512 @default.
• W2585046292 hasAuthorship W2585046292A5053295611 @default.
• W2585046292 hasAuthorship W2585046292A5058034348 @default.
• W2585046292 hasAuthorship W2585046292A5059298893 @default.
• W2585046292 hasAuthorship W2585046292A5072344236 @default.
• W2585046292 hasAuthorship W2585046292A5074255400 @default.
• W2585046292 hasAuthorship W2585046292A5075412057 @default.
• W2585046292 hasAuthorship W2585046292A5077160470 @default.
• W2585046292 hasAuthorship W2585046292A5078176598 @default.
• W2585046292 hasAuthorship W2585046292A5080269600 @default.
• W2585046292 hasAuthorship W2585046292A5090230661 @default.

• next